Wildy & Sons Ltd — The World’s Legal Bookshop Search Results for isbn: '9781781003879'

Book of the Month

Borderlines in Private Law

Edited by: William Day, Julius Grower

Price: £90.00

Buy

More Information

Lord Denning: Life, Law and Legacy

Welcome to Wildys

Watch

NEW EDITION
The Law of Rights of Light 2nd ed

Jonathan Karas

Offers for Newly Called Barristers & Students

Special Discounts for Newly Called & Students

Secondhand & Out of Print

Browse Secondhand Online

Economics of Health Law

Edited by: Ronen Avraham, David A. Hyman, Charles M. Silver

ISBN13: 9781781003879

Published: February 2016

Publisher: Edward Elgar Publishing Limited

Country of Publication: UK

Format: Hardback, 2 Volumes

Price: £586.00

Convert Currency

Buy

Despatched in 3 to 5 days.

For this two-volume collection, Professors Avraham, Hyman and Silver have selected seminal contributions by eminent scholars in the fields of law, economics and medicine. The first volume explores the effects of access to healthcare on mortality and clinical outcomes, the financing of healthcare (including payment to providers, expanding costs, health insurance and the provision of long-term care), distribution of spending and expansion of provision. The second volume covers the regulation of healthcare practice, medical malpractice and liability, public health and ethical issues.

With an authoritative new introduction by the editors, which illuminates and enhances the selection of articles, the volumes will prove an essential tool for researchers, scholars and practitioners interested in the effects on healthcare of economic and legal constraints and regulation.

Subjects:: Law and Economics, Medical Law and Bioethics

Contents:: Volume I; Introduction Ronen Avraham, David A. Hyman and Charles M. Silver; PART I ACCESS TO HEALTHCARE: HEALTHCARE, MORTALITY AND OTHER CLINICAL OUTCOMES; 1. Andrew P. Wilper, Steffie Woolhandler, Karen E. Lasser, Danny McCormick, David H. Bor and David U. Himmelstein (2009), ‘Health Insurance and Mortality in US Adults’, American Journal of Public Health, 99 (12), December, 2289–95; 2. Richard Kronick (2009), ‘Health Insurance Coverage and Mortality Revisited’, HSR: Health Services Research, 44 (4), August, 1211–31; 3. Katherine Baicker, Sarah L. Taubman, Heidi L. Allen, Mira Bernstein, Jonathan H. Gruber, Joseph P. Newhouse, Eric C. Schneider, Bill J. Wright, Alan M. Zaslavsky and Amy N. Finkelstein (2013), ‘The Oregon Experiment – Effects of Medicaid on Clinical Outcomes’, New England Journal of Medicine, 368 (18), May 2, 1713–22; PART II FINANCING HEALTH CARE; A Payment Structure and Incentives; 4. Ching-to Albert Ma and Thomas G. McGuire (1997), ‘Optimal Health Insurance and Provider Payment’, American Economic Review, 87 (4), September, 685–704; 5. Sherry Glied and Joshua Graff Zivin (2002), ‘How Do Doctors Behave When Some (But Not All) of Their Patients are in Managed Care?’, Journal of Health Economics, 21 (2), March, 337–53; 6. Thomas L. Greaney (2009), ‘Economic Regulation of Physicians: A Behavioral Economics Perspective’, Saint Louis University Law Journal, 53, 1189–209; 7. Austin B. Frakt (2011), ‘How Much Do Hospitals Cost Shift? A Review of the Evidence’, Milbank Quarterly, 89 (1), March, 90–130; B Cost Drivers; 8. Joseph P. Newhouse (1992), ‘Medical Care Costs: How Much Welfare Loss?’, Journal of Economic Perspectives, 6 (3), Summer, 3–21; 9. Burton A. Weisbrod (1991), ‘The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment’, Journal of Economic Literature, XXIX (2), June, 523–52; 10. Einer Elhauge (1997), ‘The Limited Regulatory Potential of Medical Technology Assessment’, Virginia Law Review, 82, 1525–617; C Health Insurance; 11. Kenneth J. Arrow (1963), ‘Uncertainty and the Welfare Economics of Medical Care’, American Economic Review, LIII (5), December, 941–73; 12. Mark V. Pauly (1968), ‘The Economics of Moral Hazard’, American Economic Review, 58 (3), Part I, June, 531–7; 13. Kenneth J. Arrow (1968), ‘The Economics of Moral Hazard: Further Comment’, American Economic Review, 58 (3), Part 1, June, 537–9; 14. Katherine Baicker and Amitabh Chandra (2008), ‘Myths and Misconceptions about U.S. Health Insurance’, Health Affairs, 27 (6), October, w533–w543, content.healthaffairs.org, accessed 13 August 2013; 15. Sherry A. Glied (2005), ‘The Employer-Based Health Insurance System: Mistake or Cornerstone?’, in David Mechanic, Lynn B. Rogut, David C. Colby and James R. Knickman (eds), Policy Challenges in Modern Health Care, Chapter 3, Piscataway, NJ: Rutgers University Press, 37–52; D Moral Hazard and Adverse Selection; 16. John A. Nyman (2004), ‘Is “Moral Hazard” Inefficient? The Policy Implications of a New Theory’, Health Affairs, 23 (5), September–October, 194–9; 17. David M. Cutler and Sarah J. Reber (1998), ‘Paying for Health Insurance: The Trade-off between Competition and Adverse Selection’, Quarterly Journal of Economics, 113 (2), May, 433–66; E Long-Term Care; 18. Mark V. Pauly (1990), ‘The Rational Nonpurchase of Long-Term-Care Insurance’, Journal of Political Economy, 98 (1), February, 153–68; 19. Jeffrey R. Brown and Amy Finkelstein (2011), ‘Insuring Long-Term Care in the United States’, Journal of Economic Perspectives, 25 (4), Fall, 119–41 and ‘Appendix: Calculating Loads and Comprehensiveness’,; PART III DISTRIBTUTION OF SPENDING AND CROWD-OUT; 20. Katherine Baicker, Amitabh Chandra and Jonathan S. Skinner (2005), ‘Geographic Variation in Health Care and the Problem of Measuring Racial Disparities’, Perspectives in Biology and Medicine, 48 (1), Supplement, Winter, S42–S53; 21. Tomas J. Philipson, Seth A. Seabury, Lee M. Lockwood, Dana P. Goldman and Darius N. Lakdawalla (2010), ‘Geographic Variation in Health Care: The Role of Private Markets’ and ‘Comment and Discussion’, Brookings Papers on Economic Activity, Spring, 325–55, 56–61; 22. David M. Cutler and Jonathan Gruber (1996), ‘Does Public Insurance Crowd out Private Insurance?’, Quarterly Journal of Economics, 111 (2), May, 391–430; PART IV COMPETITION AND FRAGMENTATION IN THE HEALTH CARE INDUSTRY; 23. David Hyman (2010), ‘Health Care Fragmentation: We Get What We Pay For’, in Einer Elhauge (ed.), Fragmentation of U.S. Health Care: Causes and Solutions, Chapter 2, Oxford, UK: Oxford University Press, 23–36; 24. Thomas (Tim) Greaney (2009), ‘Competition Policy and Organizational Fragmentation in Health Care’, University of Pittsburgh Law Review, 71 (2), 217–39; Index; Volume II; An introduction to both volumes by the editors appears in Volume I; PART I REGULATION OF HEALTH CARE PRACTICE; A Drugs and Devices; 1. Anup Malani and Tomas Philipson (2012), ‘The Regulation of Medical Products’, in Patricia Danzon and Sean Nicholson (eds), Oxford Handbook of the Economics of the Biopharmaceutical Industry, Chapter 5, Oxford, UK: Oxford University Press, 100–42; 2. Michelle M. Mello, Sara Abiola and James Colgrove (2012), ‘Pharmaceutical Companies’ Role in State Vaccination Policymaking: The Case of Huyman Papillomavirus Vaccination’, American Journal of Public Health, 102 (5), May, 893–8; B Licensure and Guidelines; 3. Ronen Avraham (2011), ‘Clinical Practice Guidelines – The Warped Incentives in the U.S. Healthcare System?’, American Journal of Law and Medicine, 37 (1), Spring, 7–40; 4. Shirley Svorny (1993), ‘Advances in Economic Theories of Medical Licensure’, Federation Bulletin: The Journal of Medical Licensure and Discipline, 80 (1), Spring, 27–32; C Provider Rankings; 5. Peter K. Lindenauer, Denise Remus, Sheila Roman, Michael B. Rothberg, Evan M. Benjamin, Allen Ma and Dale W. Bratzler (2007), ‘Public Reporting and Pay for Performance in Hospital Quality Improvement’, New England Journal of Medicine, 356 (5), February, 486–96; 6. David Dranove, Daniel Kessler, Mark McClellan and Mark Satterthwaite (2003), ‘Is More Information Better? The Effects of “Report Cards” on Health Care Providers’, Journal of Political Economy, 111 (3), June, 555–88; PART II MEDICAL MALPRACTICE AND LIABILITY; 7. Richard A. Epstein (1976), ‘Medical Malpractice: The Case for Contract’, American Bar Foundation Research Journal, 1 (1), 87–149; 8. Jennifer Arlen (2013), ‘Economic Analysis of Medical Malpractice Liability and Its Reform’, in Jennifer Arlen (ed.), Research Handbook on the Economics of Tort, Chapter 2, Cheltenham, UK and Northampton, MA, USA: Edward Elgar Publishing Ltd, 33–69; 9. Kenneth S. Abraham and Paul C. Weiler (1994), ‘Enterprise Medical Liability and the Evolution of the American Health Care System’, Harvard Law Review, 108 (2), December, 381–436; 10. Kathryn Zeiler, Bernard S. Black, Charles Silver, David A. Hyman and William M. Sage (2008), ‘Physicians’ Insurance Limits and Malpractice Payments: Evidence from Texas Closed Claims, 1990-2003’, Journal of Legal Studies, 36 (S2), June, S9–S45; 11. David M. Studdert, Michelle M. Mello, Atul A. Gawande, Tejal K. Gandhi, Allen Kachalia, Catherine Yoon, Ann Louise Puopolo and Trojen A. Brennan (2006), ‘Claims, Errors, and Compensation Payments in Medical Malpractice Litigation’, New England Journal of Medicine, 354 (19), May, 2024–33; 12. Daniel Kessler and Mark McClellan (1996), ‘Do Doctors Practice Defensive Medicine?’, Quarterly Journal of Economics, 111 (2), May, 353–90; 13. Daniel P. Kessler (2011), ‘Evaluating the Medical Malpractice System and Options for Reform’, Journal of Economic Perspectives, 25 (2), Spring, 93–110; 14. Ronen Avraham, Leemore S. Dafny and Max M. Schanzenbach (2012), ‘The Impact of Tort Reform on Employer-Sponsored Health Insurance Premiums’, Journal of Law Economics and Organization, 28 (4), October, 657–86; 15. Janet Currie and W. Bentley MacLeod (2008), ‘First Do No Harm? Tort Reform and Birth Outcomes’, Quarterly Journal of Economics, 123 (2), May, 795–830; PART III PUBLIC HEALTH; A Infections and Antibiotic Resistance; 16. Ramanan Laxminarayan and Anup Malani (2011), ‘Economics of Infectious Diseases’, in Sherry Glied and Peter C. Smith (eds), Oxford Handbook of Health Economics, Chapter 9, Oxford, UK: Oxford University Press, 189–205; 17. William M. Sage and David A. Hyman (2010), ‘Combatting Antimicrobial Resistance: Regulatory Strategies and Institutional Capacity’, Tulane Law Review, 84 (4), March, 781–840; B Obesity; 18. Ronen Avraham and K.A.D. Camara (2007), ‘The Tragedy of Human Commons’, Cardozo Law Review, 29 (2), November, 479–511 [33]; 19. Tomas Philipson (2001), ‘The World-Wide Growth in Obesity: An Economic Research Agenda’, Health Economics, 10, 1–7; 20. Tomas J. Philipson and Richard A. Posner (2008), 'Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy', Journal of Economic Literature, 46 (4), December, 974–82; PART IV ETHICAL ISSUES; 21. Ezekiel J. Emanuel and Margaret P. Battin (1998), ‘What are the Potential Cost Savings from Legalizing Physician-Assisted Suicide?’, New England Journal of Medicine, 339 (3), July, 167–72; 22. Judd B. Kessler and Alvin E. Roth (2012), ‘Organ Allocation Policy and the Decision to Donate’, American Economic Review, 102 (5), August, 2018–47; 23. Jason Snyder (2010), ‘Gaming the Liver Transplant Market’, Journal of Law, Economics, and Organization, 26 (3), December, 546–68; Index